Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Biocompatibility, bone healing, and safety evaluation in rabbits with an IlluminOss bone stabilization system.

McSweeney AL, Zani BG, Baird R, Stanley JRL, Hayward A, Markham PM, Kopia GA, Edelman ER, Rabiner R.

J Orthop Res. 2017 Oct;35(10):2181-2190. doi: 10.1002/jor.23532. Epub 2017 Feb 20.

2.

Evaluation of an intramedullary bone stabilization system using a light-curable monomer in sheep.

Zani BG, Baird R, Stanley JR, Markham PM, Wilke M, Zeiter S, Beck A, Nehrbass D, Kopia GA, Edelman ER, Rabiner R.

J Biomed Mater Res B Appl Biomater. 2016 Feb;104(2):291-9. doi: 10.1002/jbm.b.33380. Epub 2015 Mar 12.

3.

Particulates from hydrophilic-coated guiding sheaths embolise to the brain.

Stanley JR, Tzafriri AR, Regan K, LaRochelle A, Wong G, Zani BG, Markham PM, Bailey L, Spognardi A, Kopia GA, Edelman ER.

EuroIntervention. 2016 Mar;11(12):1435-41. doi: 10.4244/EIJY15M03_02.

4.

Safety and pharmacokinetics of sirolimus-eluting stents in the canine cerebral vasculature: 180 day assessment.

Levy EI, Hanel RA, Tio FO, Garlick DS, Bailey L, Cunningham MR, Williard C, Sherman D, Dooley JF, Kopia GA.

Neurosurgery. 2006 Oct;59(4):925-33; discussion 933-4.

PMID:
17038957
5.

Segmental vessel wall shear stress and neointimal formation after sirolimus-eluting stent implantation: physiological insights in a porcine coronary model.

Carter AJ, Wei W, Gibson L, Collingwood R, Tio F, Dooley J, Kopia GA.

Cardiovasc Revasc Med. 2005 Apr-Jun;6(2):58-64.

PMID:
16263360
6.

Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model.

Carter AJ, Aggarwal M, Kopia GA, Tio F, Tsao PS, Kolata R, Yeung AC, Llanos G, Dooley J, Falotico R.

Cardiovasc Res. 2004 Sep 1;63(4):617-24.

PMID:
15306217
7.

Update on sirolimus drug-eluting stents.

Kipshidze N, Leon MB, Tsapenko M, Falotico R, Kopia GA, Moses J.

Curr Pharm Des. 2004;10(4):337-48. Review.

PMID:
14965195
8.

Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent.

Klugherz BD, Llanos G, Lieuallen W, Kopia GA, Papandreou G, Narayan P, Sasseen B, Adelman SJ, Falotico R, Wilensky RL.

Coron Artery Dis. 2002 May;13(3):183-8.

PMID:
12131023
9.

Combination of the thromboxane receptor antagonist, sulotroban (BM 13.177; SK&F 95587), with streptokinase: demonstration of thrombolytic synergy.

Kopia GA, Kopaciewicz LJ, Ohlstein EH, Horohonich S, Storer BL, Shebuski RJ.

J Pharmacol Exp Ther. 1989 Sep;250(3):887-95.

PMID:
2528630
10.

Evaluation of the effect of evan's blue and triphenyltetrazolium chloride dyes on myeloperoxidase activity in canine cardiac tissue.

Griswold DE, Hillegass L, Hill DE, Sherief HT, Kopia GA.

J Pharmacol Methods. 1989 Mar;21(1):13-9.

PMID:
2539540
11.

Demonstration of specific dopamine-1 receptor-mediated coronary vasodilation in the anesthetized dog.

Kopia GA, Valocik RE.

J Pharmacol Exp Ther. 1989 Jan;248(1):215-21.

PMID:
2563287
12.

Coronary vascular activity of the novel inotropic pro-drug ibopamine and the de-esterified active form epinine.

Ohlstein EH, Kopia GA, Ruffolo RR Jr.

Arzneimittelforschung. 1988 Dec;38(12):1790-2.

PMID:
3245851
13.

Evaluation of the acute hemodynamic effects and pharmacokinetics of coronary thrombolysis produced by intravenous tissue-type plasminogen activator in the anesthetized dog.

Kopia GA, Kopaciewicz LJ, Fong KL, Crysler CS, Boyle K, Ruffolo RR Jr.

J Cardiovasc Pharmacol. 1988 Sep;12(3):308-16.

PMID:
2464103
15.

Effects of the thromboxane receptor antagonist SK&F 88046 in the canine, monkey and human coronary vasculature.

Ohlstein EH, Kopia GA, Zeid RL, Valocik RW, Horohonich S, Hieble JP, Wasserman MA.

Prostaglandins. 1988 Jul;36(1):69-84.

PMID:
3175024
16.

Coronary thrombolysis with intravenous streptokinase in the anesthetized dog: a dose-response study.

Kopia GA, Kopaciewicz LJ, Ruffolo RR Jr.

J Pharmacol Exp Ther. 1988 Mar;244(3):956-62.

PMID:
3252043
17.

Dose-dependent pharmacokinetics of recombinant tissue-type plasminogen activator in anesthetized dogs following intravenous infusion.

Fong KL, Crysler CS, Mico BA, Boyle KE, Kopia GA, Kopaciewicz L, Lynn RK.

Drug Metab Dispos. 1988 Mar-Apr;16(2):201-6.

PMID:
2898333
18.

Inhibition of leukotriene D4-induced coronary vasoconstriction by leukotriene antagonists in the anesthetized dog.

Kopia GA, Valocik RE, Torphy TJ, Cieslinksi LB, Sarau HM, Foley JJ, Wasserman MA.

J Pharmacol Exp Ther. 1987 Apr;241(1):174-80.

PMID:
2437287
19.

Antifibrillatory action of bretylium: role of the sympathetic nervous system.

Kopia GA, Lucchesi BR.

Pharmacology. 1987;34(1):37-47.

PMID:
3575413
20.

Alpha adrenoceptor regulation of coronary artery blood flow in normal and stenotic canine coronary arteries.

Kopia GA, Kopaciewicz LJ, Ruffolo RR Jr.

J Pharmacol Exp Ther. 1986 Dec;239(3):641-7.

PMID:
2879028
21.

Importance of receptor regulation in the pathophysiology and therapy of congestive heart failure.

Ruffolo RR Jr, Kopia GA.

Am J Med. 1986 Feb 28;80(2B):67-72. Review.

PMID:
2868661
22.

Antiarrhythmic and electrophysiologic actions of clofilium in experimental canine models.

Kopia GA, Eller BT, Patterson E, Shea MJ, Lucchesi BR.

Eur J Pharmacol. 1985 Oct 8;116(1-2):49-61.

23.
24.

Antiarrhythmic and cardiovascular actions of the new antibiotic agent pirlimycin adenylate.

Kopia GA, Driscoll EM, Yeung KF, Lucchesi BR.

Pharmacology. 1983;27(5):255-66.

PMID:
6606809
25.

Cardiac arrhythmias induced by guanethidine in cats anesthetized with halothane.

Condouris GA, Kopia GA.

Eur J Pharmacol. 1980 Dec 5;68(3):257-65.

PMID:
7202491
26.

Levo-bunolol and propranolol: further evaluation of oral beta-blocking activity in conscious dogs.

Commarato MA, Giardino EC, Kopia GA, Kaplan HR.

Arch Int Pharmacodyn Ther. 1977 Apr;226(2):205-13.

PMID:
327960
27.

Supplemental Content

Loading ...
Support Center